These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 30288874)

  • 1. New alcohol flushing in a patient with atopic dermatitis under therapy with dupilumab.
    Herz S; Petri M; Sondermann W
    Dermatol Ther; 2019 Jan; 32(1):e12762. PubMed ID: 30288874
    [No Abstract]   [Full Text] [Related]  

  • 2. Dupilumab (Dupixent) for moderate to severe atopic dermatitis.
    Med Lett Drugs Ther; 2017 Apr; 59(1519):64-66. PubMed ID: 28419072
    [No Abstract]   [Full Text] [Related]  

  • 3. Remittive effect of Dupilumab in atopic dermatitis.
    Treister AD; Lio PA
    Dermatol Ther; 2018 Nov; 31(6):e12711. PubMed ID: 30253014
    [No Abstract]   [Full Text] [Related]  

  • 4. Dupilumab for treatment of atopic dermatitis.
    Seegräber M; Srour J; Walter A; Knop M; Wollenberg A
    Expert Rev Clin Pharmacol; 2018 May; 11(5):467-474. PubMed ID: 29557246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The beginning of biological treatment era in the atopic dermatitis management.
    D'erme AM
    Dermatol Ther; 2016 May; 29(3):208-9. PubMed ID: 26331894
    [No Abstract]   [Full Text] [Related]  

  • 6. Recall dermatitis at patch test sites in an atopic dermatitis patient treated with dupilumab.
    Collantes-Rodríguez C; Jiménez-Gallo D; Ossorio-García L; Villegas-Romero I; Linares-Barrios M
    Contact Dermatitis; 2019 Jan; 80(1):69-70. PubMed ID: 30334260
    [No Abstract]   [Full Text] [Related]  

  • 7. Two Cancer Patients Receiving Dupilumab for Treatment of Atopic Dermatitis.
    Fowler E; Rosen J; Lev-Tov H; Yosipovitch G
    Acta Derm Venereol; 2019 Sep; 99(10):899-900. PubMed ID: 31037315
    [No Abstract]   [Full Text] [Related]  

  • 8. Ethanol-induced flushing with topical pimecrolimus use.
    Ogunleye T; James WD
    Dermatitis; 2008; 19(2):E1-2. PubMed ID: 18413100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal Antibodies for Atopic Dermatitis: Progress and Potential.
    Vakharia PP; Silverberg JI
    BioDrugs; 2017 Oct; 31(5):409-422. PubMed ID: 28853008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.
    Beck LA; Thaçi D; Hamilton JD; Graham NM; Bieber T; Rocklin R; Ming JE; Ren H; Kao R; Simpson E; Ardeleanu M; Weinstein SP; Pirozzi G; Guttman-Yassky E; Suárez-Fariñas M; Hager MD; Stahl N; Yancopoulos GD; Radin AR
    N Engl J Med; 2014 Jul; 371(2):130-9. PubMed ID: 25006719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dupilumab: a revolutionary emerging drug in atopic dermatitis and its possible role in pemphigus.
    Tavakolpour S
    Dermatol Ther; 2016 Sep; 29(5):299. PubMed ID: 26800435
    [No Abstract]   [Full Text] [Related]  

  • 12. Risk Factors for Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis.
    Treister AD; Kraff-Cooper C; Lio PA
    JAMA Dermatol; 2018 Oct; 154(10):1208-1211. PubMed ID: 30167653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers.
    Bakker DS; Ariens LFM; Giovannone B; Hijnen D; Delemarre EM; Knol E; Nierkens S; de Bruin-Weller MS; Thijs JL; Drylewicz J
    Allergy; 2020 Dec; 75(12):3287-3289. PubMed ID: 33305359
    [No Abstract]   [Full Text] [Related]  

  • 14. Evaluation of Potential Disease-Mediated Drug-Drug Interaction in Patients With Moderate-to-Severe Atopic Dermatitis Receiving Dupilumab.
    Davis JD; Bansal A; Hassman D; Akinlade B; Li M; Li Z; Swanson B; Hamilton JD; DiCioccio AT
    Clin Pharmacol Ther; 2018 Dec; 104(6):1146-1154. PubMed ID: 29498038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early onset of alopecia areata after dupilumab introduction in a patient with atopic dermatitis.
    Barbarin C; Hosteing S; Nosbaum A; Allouchery M; Celerier P
    Eur J Dermatol; 2019 Oct; 29(5):542-543. PubMed ID: 31789276
    [No Abstract]   [Full Text] [Related]  

  • 16. Dupilumab for Atopic Dermatitis, a Possible Risk Factor of Juvenile Ischemic Stroke: A Case Report.
    Iwase R; Ishiguro T; Fujita K; Ishibashi S; Yokota T
    J Stroke Cerebrovasc Dis; 2020 Jun; 29(6):104763. PubMed ID: 32265139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dupilumab-Induced Facial Flushing After Alcohol Consumption.
    Brownstone ND; Reddy V; Thibodeaux Q; Myers B; Chan S; Liao W; Bhutani T
    Cutis; 2021 Aug; 108(2):106-107. PubMed ID: 34735321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dupilumab, A Monoclonal Antibody for Atopic Dermatitis: A Review of Current Literature.
    Blakely K; Gooderham M; Papp K
    Skin Therapy Lett; 2016 Mar; 21(2):1-5. PubMed ID: 27223113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dupilumab in atopic dermatitis, a protocol for SARS-COV-2-infected patients.
    Ordóñez-Rubiano MF; Campo I; Casas M
    Dermatol Ther; 2020 Nov; 33(6):e14172. PubMed ID: 32779378
    [No Abstract]   [Full Text] [Related]  

  • 20. Atopic-like dermatitis after secukinumab injection: A case report.
    Burlando M; Cozzani E; Russo R; Parodi A
    Dermatol Ther; 2019 Jan; 32(1):e12751. PubMed ID: 30238583
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.